Document Security Systems

DSS, Inc. engages in the development and distribution of paper products designed to protect valuable information from unauthorized scanning, copying, and digital imaging. It operates through the following segments: Product Packaging, Commercial Lending, Biotechnology, Direct Marketing, and Securities and Investment Management. The Product Packaging segment operates in the paper board folding carton, smart packaging, and document security printing markets. The Commercial Lending segment provides commercial loans and on acquiring equity positions in undervalued commercial bank(s), bank holding companies and non-banking licensed financial companies operating in the United States, Southeast Asia, Taiwan, Japan, and South Korea. The Biotechnology segment invests in or acquires companies in the bio-health and biomedical fields, including businesses focused on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune related diseases. The Direct Marketing segment provides services to assist companies in the emerging growth gig business model of peer-to-peer decentralized sharing marketplaces. The Securities and Investment Management segment develops and/or acquire assets and investments in the securities trading and/or funds management arena and to pursue, among other product and service lines, real estate investment funds, broker dealers and mutual funds management. The company was founded on June 16, 1984 and is headquartered in West Henrietta, NY.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DSS, Inc. engages in the development and distribution of paper products designed to protect valuable information from unauthorized scanning, copying, and digital imaging. It operates through the following segments: Product Packaging, Commercial Lending, Biotechnology, Direct Marketing, and Securities and Investment Management. The Product Packaging segment operates in the paper board folding carton, smart packaging, and document security printing markets. The Commercial Lending segment provides commercial loans and on acquiring equity positions in undervalued commercial bank(s), bank holding companies and non-banking licensed financial companies operating in the United States, Southeast Asia, Taiwan, Japan, and South Korea. The Biotechnology segment invests in or acquires companies in the bio-health and biomedical fields, including businesses focused on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune related diseases. The Direct Marketing segment provides services to assist companies in the emerging growth gig business model of peer-to-peer decentralized sharing marketplaces. The Securities and Investment Management segment develops and acquires assets and investments in the securities trading and funds management arena and to pursue, among other product and service lines, real estate investment funds, broker dealers and mutual funds management. The company was founded on June 16, 1984 and is headquartered in West Henrietta, NY.

NEW YORK, Nov. 28, 2023 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS), a multinational company operating nine (9) diversified business lines developed through strategic acquisitions to build shareholder value through periodic spinoffs to its shareholders, announced today that its wholly-owned subsidiary, Premier Packaging, signed a contract extension with an existing client for the next three years totaling a minimum of $12 Million with a fourth year extension option bringing the potential total revenue to over $15 Million. Frank D. Heuszel, President and CEO of DSS, Inc., said, “We are very pleased to see that our capital investment to increase production capacity and economies of scale at Premier Packaging continues to result in satisfied clients and increasing revenues.

Premier Packaging, a Wholly-Owned Subsidiary of DSS, Inc., Secures Contract Extension with Major Retailer Worth Up to $15 Million over Four Years

DSS Shareholders to Benefit from Reduction in Common Stock of Impact Biomedical DSS Shareholders to Benefit from Reduction in Common Stock of Impact Biomedical

DSS, Inc. Subsidiary Files Current Report on Form 8-K Disclosing Reverse Split of Outstanding and Issued Common Stock and Conversion of Certain Holder's Common Stock

Company intends to cure the deficiency and return to compliance with NYSE American standard Company intends to cure the deficiency and return to compliance with NYSE American standard

DSS Inc. Receives Notice of Non-Compliance with NYSE American Trading Share Price Listing Rule

NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) -- DSS, Inc.(NYSE American: DSS) ("DSS") announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission ("SEC") relating to the proposed initial public offering of the Company's wholly-owned subsidiary, Impact Biomedical (hyperlink: https://www.impactbiomedinc.com/). DSS, Inc. intends to list Impact Biomedical on the NYSE American exchange. The number of shares of Class A common stock to be offered and the price range for the proposed offering have not yet been determined. The offering is subject to market conditions.

DSS, Inc. Announces Filing of Registration Statement on Form S-1 for Initial Public Offering of Impact Biomedical

CEO Highlights Expected IPO of Impact Biomedical and Progress in Subsidiaries CEO Highlights Expected IPO of Impact Biomedical and Progress in Subsidiaries

DSS Inc. Issues Letter to Shareholders

Jim Monaghan Appointed Chief Operating Officer and Chief Compliance Officer; Michael Cheah Joins as Portfolio Manager and Head of Fixed Income Jim Monaghan Appointed Chief Operating Officer and Chief Compliance Officer; Michael Cheah Joins as Portfolio Manager and Head of Fixed Income

DSS Inc. Expands DSS Wealth Management, Inc.'s Management Team for Ramp Up of Asset Management Subsidiary

DSS Shareholders of Record on July 10, 2023 to Receive Four Shares of Impact Biomedical Inc. for Every One Share of DSS, Inc. DSS Shareholders of Record on July 10, 2023 to Receive Four Shares of Impact Biomedical Inc. for Every One Share of DSS, Inc.

DSS Inc. Announces Distribution Date of August 8, 2023 for Spinoff of Impact BioMedical Inc.

ROCHESTER, N.Y., July 05, 2023 (GLOBE NEWSWIRE) -- DSS Wealth, Inc., a wholly owned subsidiary of DSS, Inc. and advisor to DSS AmericaFirst Quantitative Funds, is pleased to announce the appointment of Daniel Lew as Chief Investment Officer and Portfolio Manager. With over three decades of experience in investment management, security analysis, and institutional client advisory, Mr. Lew brings a wealth of knowledge and expertise to his new role.

DSS Inc. Appoints Daniel Lew as Chief Investment Officer and Portfolio Manager for DSS Wealth, Inc.

Shareholders of Record on July 10, 2023 to Receive Four Shares of Impact Biomedical Inc. for Every One Share of DSS, Inc. on a Future Distribution Date Shareholders of Record on July 10, 2023 to Receive Four Shares of Impact Biomedical Inc. for Every One Share of DSS, Inc. on a Future Distribution Date

DSS Inc. Announces Updated Shareholder of Record Date for Spinoff of Impact BioMedical Inc.

DSS Shareholders of Record on June 30 to Receive 4 Shares for Every 1 DSS Share DSS Shareholders of Record on June 30 to Receive 4 Shares for Every 1 DSS Share

DSS, Inc. Announces Record and Distribution Date for Impact Biomedical Spin-Off Special Dividend

ROCHESTER, N.Y., May 16, 2023 (GLOBE NEWSWIRE) -- DSS, Inc. (“DSS” or the “Company”) (NYSE American: DSS), a multinational company operating nine business divisions through strategic acquisitions and development to build shareholder value through periodic spinoffs, announced today its financial results for the First Quarter, 2023.

DSS, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023

Distribution Date of May 4, 2023 Set for Stock Dividend of Sharing Services Shares (SHRG) Distribution Date of May 4, 2023 Set for Stock Dividend of Sharing Services Shares (SHRG)

DSS Inc. Announces Distribution Date of Sharing Services Shares to DSS Shareholders

ROCHESTER, N.Y., April 19, 2023 (GLOBE NEWSWIRE) -- DSS, Inc. (“DSS” or the “Company”) (NYSE American: DSS), a multinational company operating nine business divisions through strategic acquisitions and development to build shareholder value through periodic spinoffs, announced that the Company plans to distribute to its stockholders common stock of Sharing Services Global Corporation (“Sharing Services” or “SHRG”) that is beneficially held by DSS, directly and through its subsidiary, Decentralized Sharing Systems, Inc. (“DSSI”).

DSS, Inc. Announces Plan to Distribute Common Stock of Sharing Services Global Corporation to Shareholders

Company to Highlight Strong Revenue Growth and Planned Spinoffs to DSS Shareholders Company to Highlight Strong Revenue Growth and Planned Spinoffs to DSS Shareholders

DSS, Inc. to Present at Emerging Growth Conference April 19 at 1:45 PM

CEO Highlights Business Plan including Spin-Offs CEO Highlights Business Plan including Spin-Offs

DSS Announces Letter to Shareholders

ROCHESTER, N.Y., Aug. 30, 2022 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS), a multinational company operating businesses within nine divisions and strategically acquiring and developing assets to enrich the value of its shareholders through calculated IPO spinoffs and a parametric share distribution strategy, today announced it received a notice (the "Notice") stating that the Company is not in compliance with the NYSE American's continued listing requirements under the timely filing criteria established in the NYSE American Company Guide. Under Section 1007 of the NYSE American Company Guide, the Company could be granted up to 12 months to cure the late filer deficiency. The initial six month period to regain compliance is automatic and the additional six months is only granted upon request by the Company and approval by the NYSE.

DSS Receives New York Stock Exchange Notice Regarding Late Form 10-Q Filing

Blue Hat Interactive Entertainment Technology

Boxed

Velo3D

Penny stocks to watch under $5. The post Penny Stocks To Buy This Week?

Penny Stocks To Buy This Week? 4 Under $5 To Watch Before Monday

ROCHESTER, N.Y., July 21, 2022 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS), a multinational company operating businesses within nine divisions and strategically acquiring and developing assets to enrich the value of its shareholders through calculated IPO spinoffs and a parametric share distribution strategy, today announced Global BioLife, Inc. (“Global BioLife”), a subsidiary of the Company's wholly owned subsidiary Impact BioMedical, Inc. (“Impact BioMedical”), executed a license agreement with ProPhase BioPharma, Inc. (“PBIO”), a subsidiary of ProPhase Labs, Inc. (Nasdaq: PRPH), a rapidly growing and diversified diagnostics, genomics and biotech company, for Global BioLife's Linebacker portfolio (LB-1 and LB-2), two patented small molecule PIM kinase inhibitors with significant potential across multiple therapeutic indications.

DSS Announces Licensing of Impact BioMedical's Linebacker Portfolio to ProPhase Labs

ROCHESTER, N.Y., July 13, 2022 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS), a multinational company operating businesses within nine divisions and strategically acquiring and developing assets to enrich the value of its shareholders through calculated IPO spinoffs and a parametric share distribution strategy, today announced the expansion of its Board of Directors with the appointment of two independent directors, Frankie Wong, a 20-year veteran of public-company financial reporting, and Joanne Wong Hiu Pan, an investment manager with BMI Funds Management Ltd., the leading financial advisor in Hong Kong.

DSS Strengthens and Expands Board with Appointment of Two Independent Directors

HENRIETTA, N.Y., June 28, 2022 (GLOBE NEWSWIRE) -- Impact Biomedical, Inc., a wholly owned subsidiary of DSS, Inc. (NYSE American: DSS), along with its scientific research partner Global Research and Discovery Group Sciences (GRDG), announced today that it signed a license agreement with ProPhase Labs (NASDAQ: PRPH) for Equivir, which has shown potential as a treatment to limit the occurrence of or reduce the risk or severity of viral outbreaks.

Impact BioMedical Announces License Agreement with ProPhase Labs to Produce and Distribute Viral-Fighting Compound Equivir

China is one of the leading markets globally for insect repellants China is one of the leading markets globally for insect repellants

DSS's Impact BioMedical Receives China Patent for its Functional Fragrance Formulation Mosquito Repellant

ROCHESTER, N.Y., May 06, 2022 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS), a multinational company operating businesses within nine divisions and strategically acquiring and developing assets to enrich the value of its shareholders through calculated IPO spinoffs and a parametric share distribution strategy, today announced that an interview with Chief Operating Officer, Jason Grady, will air on The RedChip Money Report® on Bloomberg U.S., this Saturday May 7th, at 7 p.m. Eastern Time (ET). Bloomberg U.S. is available in an estimated 73 million homes across the United States.

DSS, Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report®

Clover Health Investments

GSX Techedu Inc.

Here are three penny stocks to add to your watchlist right now The post 3 Hot Penny Stocks to Buy Now? Check These Small-Caps Out  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Hot Penny Stocks to Buy Now? Check These Small-Caps Out

Coeur Mining

CTI BioPharma

Can these penny stocks climb this month? The post Hot Penny Stocks to Watch in March 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Hot Penny Stocks to Watch in March 2022

ROCHESTER, N.Y., Feb. 28, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by DSS, Inc. (NYSE American: DSS), please note that in paragraph fourteen, [With more than $1.7 trillion in assets…] should read [With more than $1.7 billion in assets…]. The corrected release follows:

News for Document Security Systems Stock (DSS)